Study wrapper · #438
Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study.
Editor's note
A prospective observational study of 64 adults with chronic plaque psoriasis and obesity given low-dose tirzepatide (2.5 titrated to 5 mg weekly) while maintained on stable ixekizumab. At 24 weeks the study reported about 10% weight loss and significant improvements in fasting glucose, LDL, triglycerides and liver enzymes, plus a 76% drop in PASI score. The metabolic changes are consistent with tirzepatide's established weight effects. The psoriasis-severity result needs a heavy caveat: patients stayed on an active biologic (ixekizumab), so the PASI improvement cannot be attributed to tirzepatide, and there is no control arm. This is a single-arm, uncontrolled cohort, useful for showing metabolic parameters moved in a psoriasis population, but not for isolating a skin benefit. Read the metabolic signal as supportive and the skin-severity figure as confounded and hypothesis-level at best.
Plain-language abstract
This study looked at whether tirzepatide improves weight and metabolic health in people who have both psoriasis and obesity. Sixty-four adults were given a low dose of tirzepatide (building from 2.5 to 5 mg weekly) while continuing their existing psoriasis medication, ixekizumab. After 24 weeks, they had lost about 10% of their body weight, and their blood sugar, cholesterol, triglycerides and liver enzyme levels all improved. Their psoriasis severity scores also dropped sharply. However, because everyone stayed on their regular psoriasis drug and there was no comparison group, the improvement in skin symptoms cannot be credited to tirzepatide; it may simply reflect the ongoing psoriasis treatment. The weight and metabolic improvements fit with what tirzepatide is known to do. The authors suggest tirzepatide could contribute to managing metabolic health in people with psoriasis and obesity, though a controlled study would be needed to separate the effects.